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Abstract: The Ehlers–Danlos syndromes (EDS) are a heterogeneous group of heritable disorders
affecting connective tissues. The mutations causing the various forms of EDS in humans are well
characterized, but the genetic mutations causing EDS-like clinical pathology in dogs are not known,
thus hampering accurate clinical diagnosis. Clinical analysis of two independent cases of skin
hyperextensibility and fragility, one with pronounced joint hypermobility was suggestive of EDS.
Whole-genome sequencing revealed de novo mutations of COL5A1 in both cases, confirming the
diagnosis of the classical form of EDS. The heterozygous COL5A1 p.Gly1013ValfsTer260 mutation
characterized in case 1 introduced a premature termination codon and would be expected to result in
α1(V) mRNA nonsense-mediated mRNA decay and collagen V haploinsufficiency. While mRNA was
not available from this dog, ultrastructural analysis of the dermis demonstrated variability in collagen
fibril diameter and the presence of collagen aggregates, termed ‘collagen cauliflowers’, consistent
with COL5A1 mutations underlying classical EDS. In the second case, DNA sequencing demonstrated
a p.Gly1571Arg missense variant in the COL5A1 gene. While samples were not available for further
analysis, such a glycine substitution would be expected to destabilize the strict molecular structure of
the collagen V triple helix and thus affect protein stability and/or integration of the mutant collagen
into the collagen V/collagen I heterotypic dermal fibrils. This is the first report of genetic variants
in the COL5A1 gene causing the clinical presentation of EDS in dogs. These data provided further
evidence of the important role of collagen V in dermal collagen fibrillogenesis. Importantly, from
the clinical perspective, we showed the utility of DNA sequencing, combined with the established
clinical criteria, in the accurate diagnosis of EDS in dogs.
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1. Introduction
The Ehlers–Danlos syndromes (EDS) are a heterogeneous group of heritable disorders affecting
connective tissue. In humans, variable clinical manifestations affecting primarily the skin, joints,
ligaments, blood vessels, and internal organs have been reported. EDS has also been seen in many
animal species, including horses [1], mink [2], rabbits [3], dogs [4–14], and cats [15–18].
Abnormal collagen fibril formation is the hallmark of several types of human EDSs, including the
classical form [19]. In the classical form of EDS, mutations in COL5A1 and COL5A2, which encode the
α1- and α2-chain of type V collagen, have been reported [20–26]. Type V collagen is a quantitatively
minor fibril-forming collagen. Several isoforms exist, but the most widely distributed form is the
[α1(V)]2α2(V) heterotrimer that co-assembles with type I collagen into heterotypic type I/V collagen
fibrils in the extracellular matrix. Type V collagen is thought to regulate the diameter of these fibrils by
retention of its large N-propeptide domain, which projects above the surface of the collagen fibril [27].
In humans, mutations in COL5A1 and COL5A2 lead to characteristic collagen abnormalities in the
skin with variability in collagen fibril diameter and the presence of collagen aggregates, termed
‘collagen cauliflowers’ [28]. Abnormal collagen structure and fibril formation, in turn, contribute to the
clinical signs seen in classic EDS, including hyperextensible skin, generalized joint hypermobility, and
generalized connective tissue fragility [29].
We reported here three dogs with two different genetic variants in the COL5A1 gene affecting
collagen synthesis and structure, analogous to classical EDS in human patients. Furthermore, we
described histopathological and ultrastructural findings associated with the COL5A1 variants in these
animals. Collagen protein analysis of one affected individual was also performed.
2. Materials and Methods
2.1. Ethics
The collection of blood and skin samples from case 1 and the related controls (FB and MY)
were approved by the Murdoch Children’s Research Institute Animal Ethics Committee (Approval
# A815). Blood and skin samples for cases 2 and 3 (RA) were collected as part of routine veterinary
diagnostic assessment. For biopsy samples, animals were sedated with diazepam 0.5 mg/kg IV
(Diapharm® 10 mg/mL, Pharma5, Morocco) and ketamine 6 mg/kg IV (Imalgene® 1000, Merial, France)
via peripheral catheter to achieve a moderate level of sedation. Biopsies were collected as per standard
techniques, and the animals recovered uneventfully. Taking blood samples from healthy control dogs
for genetic analysis was approved by the “Cantonal Committee For Animal Experiments” (Canton of
Bern; permit 75/16).
2.2. Histopathology
2.2.1. Case 1
One 6 mm diameter punch biopsy was obtained from the dorsum of the 6-month-old Labrador,
fixed in 10% neutral-buffered formalin, processed routinely, and embedded in paraffin wax.
Four-to-five-micron-thick sections were stained with hematoxylin and eosin (H&E), Masson’s Trichrome
(MT), and Verhoeff van Gieson (VVG) stains at the University of Georgia, College of Veterinary Medicine
Histology Laboratory. As a control, a punch biopsy was obtained from the abdominal region of a
10-month-old, intact male, Labrador dog, fixed in formalin, processed routinely, and stained with H&E,
MT, and VVG for comparison. Slides were reviewed by a board-certified veterinary pathologist (SK).
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2.2.2. Cases 2 and 3
One 8 mm punch biopsy from the lateral thorax was investigated histologically. The biopsy was
fixed in 10% buffered formalin and processed routinely. The slide was stained with hematoxylin and
eosin (H&E) prior to histopathological examination by a board-certified veterinary pathologist (MW).
2.3. Transmission Electron Microscopy (TEM)
For electron microscopy, dermal samples were fixed in 0.1 M sodium cacodylate containing
2.5% glutaraldehyde; after rinsing, the samples were post-fixed in 1% aqueous osmium tetroxide,
dehydrated in an alcohol series, and embedded in Epon 812. Seventy-nanometer ultrathin sections
were cut and observed on a Tecnai F30 (FEI, Eindhoven, NL, USA) with an extraction voltage of 200 kV.
Micrographs were taken using a Gatan UltraScan 1000 (Gatan, Pleasanton, CA, USA).
2.4. Biochemical Analysis of Dermis
Full-thickness dermal biopsies were diced with a scalpel and defatted by gentle shaking with
cold chloroform:methanol (2,1) for 24 h. Tissue was washed with cold methanol and dried under
vacuum. Dried tissue was re-hydrated in 50 mM Tris/HCl, pH 7.5 containing 0.15 M NaCl. To assist
in the uniformity of extraction, the re-hydrated tissue was snap-frozen and powered under liquid
nitrogen. For collagen analysis, a sequential extraction protocol was used to extract the successively
more cross-linked collagen matrix, as previously described [30]. The freeze-milled dermis was first
extracted with 0.15 M NaCl, 50 mM Tris-HCl buffer for 24 h at 4 ◦C to remove the soluble collagens
followed by extraction with 4 M guanidine hydrochloride (GuHCl) in Tris-HCl buffer (pH 7.4), then
0.5 M acetic acid, and finally digestion with pepsin at 100 µg/mL in 0.5 M acetic acid to sequentially
extract the successively more cross-linked and thus mature collagen matrix. To enrich for collagen V,
selective salt precipitation of portions of the pepsin extracted collagen was performed [31]. Collagen
chains in each extract were analyzed on SDS-gradient polyacrylamide gels (3–8%, Tris-Acetate Gel,
Novex Life Technologies, Carlsbad, CA, USA), visualized by Coomassie Brilliant Blue staining and
quantified, as described previously [30]. Pepsin-soluble collagen from rat tail tendon was run on each
gel as a standard for quantitation.
2.5. DNA Extraction and Whole-Genome Sequencing
Genomic DNA was isolated from EDTA blood samples of the investigated dogs. For case 1 and
case 2, an Illumina PCR-free TruSeq fragment library with ~390 bp insert size was prepared. We
collected ~153 and 211 million 2 × 150 bp paired-end reads or ~18× and ~25× coverage on an Illumina
HiSeq 3000 instrument for cases 1 and 2, respectively. The reads were mapped to the CanFam3.1 dog
reference genome assembly and aligned using Burrows–Wheeler Aligner (BWA) version 0.7.5a [32]
with default settings. The generated SAM file was converted to a BAM file, and the reads were
sorted by coordinate using SAMtools [33]. Picard tools (http://sourceforge.net/projects/picard/) were
used to mark PCR duplicates. To perform local realignments and to produce a cleaned BAM file,
we used the Genome Analysis Tool Kit (GATK version 2.4.9, 50) [34]. GATK was also used for base
quality recalibration with canine dbsnp version 139 data as a training set. The sequence data were
deposited under the study accession PRJEB16012 and sample accessions SAMEA104091568 (case 1),
and SAMEA4867923 (case 2), at the European Nucleotide Archive. Additionally, we used 356 additional
whole-genome sequences as controls, which were either publicly available [35], produced during other
projects of our group or contributed by members of the Dog Biomedical Variant Database Consortium.
Putative SNVs were identified in each of the 358 samples individually using GATK HaplotypeCaller
in gVCF mode [36]. Subsequently, all sample gVCF files were joined using Broad GenotypeGVCFs
walker (-stand_emit_conf 20; -stand_call_conf 30). Filtering was performed using the variant filtration
module of GATK using the following standard filters: SNPs: Quality by Depth: QD < 2; Mapping quality:
MQ < 40; Strand filter: FS > 60; MappingQualityRankSum: MQRankSum < −12.5; ReadPosRankSum <
−8 and INDELs: Quality by Depth: QD < 2; Strand filter: FS > 200. The functional effects of the called
variants were predicted using SnpEFF software [37] together with the NCBI annotation release 105 on
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CanFam 3.1. Identified sequence variants were confirmed by Sanger sequencing of PCR amplicons.
Targeted genotyping of additional dogs was also done by Sanger sequencing.
3. Results
3.1. Clinical Assessment
3.1.1. Case 1
A 4-month-old male intact Labrador was examined for several small skin lacerations of the distal
limbs, hock, and tail base. On physical examination, the dog was found to be clinically healthy, with
normal skeletal development. Several seroma-like swellings were noted in the regions of skin trauma
(hocks, tail base). Aspirates taken from these swellings revealed moderate numbers of erythrocytes
with fewer neutrophils and macrophages with proteinaceous debris. These findings were consistent
with a seroma or hematoma formation, and the dog was treated with amoxycillin/clavulanic acid
(Clavulox®, Zoetis, Ryde, Australia) and firocoxib (Previcox®, Zoetis, Ryde, Australia).
Two months after initial presentation, the dog was again examined for ongoing seroma formation
and joint abnormalities. On physical examination, evidence of generalized joint hyperextensibility with
a range of motion greater than 180◦ (Figure 1) and skin hyperextensibility (Figures 2 and 3) and fragility
was noted. The dog had a skin extensibility test [38] of 23.5% (normal < 14.5%) [39]. A complete
blood count revealed mild anemia of 4.87 × 1012/L (5.5–8.5), HCT 0.33 L/L (0.37–0.55), Hb 113 g/L
(120–180), and a normal white cell count. Serum biochemistry showed a mild hypoalbuminemia
21 g/L (28–42) and hypoproteinemia 47 g/L (54–78). Other serum abnormalities included a moderate
hyperphosphatemia, mild elevation in ALP, and decrease in creatinine that were all considered within
normal limits for a young dog. At this time, due to the ongoing joint hypermobility and skin lacerations
with the suspicion of genetic collagen disease, the owners elected to humanely euthanize the dog.
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3.1.2. Cases 2 and 3
Two young adult mixed breed dogs were presented for hematomas and skin lacerations after mild
trauma. The dogs (siblings) were adopted from an animal shelter in the southeast region of Morocco.
The prior clinical history and onset of clinical signs were unknown, though it was noted that the dam
was unaffected. On physical examination, the dogs were found to be clinically healthy, with normal
skeletal development. Bruising and skin lacerations were noted on the carpi with oozing, hemorrhagic
zones of 3–4 cm in size with disruption of the skin barrier (splitting of the skin) in these regions (case
2). Bruising and wounds were noted to occur after only mild trauma. There was hyperelasticity of
the elbows (Figure 4) and tarsi as well as the skin of the neck (Figure 5) and flank (case 2 and 3), with
evidence of the previous scarring on the neck (case 2). The rest of the clinical exam was unremarkable
for both dogs. The presence or absence of joint hypermobility was not described in the medical records.
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On routine screening of blood work for case 2, the hematocrit was normal at 0.48 L/L (0.37–0.55)
and total solids 54 g/L (54–78). While skin biopsy of case 2 and 3 was performed, no further diagnostic
testing was undertaken. The outcome of these dogs is currently not known.
3.2. Histopathology
3.2.1. Case 1
Histological examination of skin from the 4-month-old Labrador revealed dermal collagen fiber
abnormalities, characterized by fiber disarray, variability in fiber diameter, and multifocal fiber
clumping (Figure 6, Panels A and B). Collagen clumps stained hypereosinophilic on H&E and dark red
on an MT stain. On the VVG stain, dermal elastic fibers were mildly increased in number multifocally,
irregularly distributed throughout the dermis, and variably sized. The space between collagen fibers
as well as the number and arrangement of dermal fibroblasts was similar between the affected and
control dogs. The epidermis was of normal thickness in both the affected and control dog skin.
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Figure 6. Comparison of histopathology findings in the skin of two dogs with Ehlers–Danlos syndromes
(EDS)-like syndrome attributed to different mutations in the COL5A1 gene. (A,B): Photomicrographs
of skin from the dorsum of the dog (case 1) with EDS-like syndrome attributed to a single nucleotide
deletion and premature stop codon formation in the COL5A1 gene. Throughout the dermis, there is
collagen fiber disorganization with great variation in fiber diameter, length, and staining intensity.
200× original magnification; bar = 50 microns. (B): Collagen fibers frequently form variably sized,
hypereosinophilic clumps (open arrowheads). 200× original magnification; bar = 50 microns. (C,D):
Photomicrographs of skin from one of the affect d siblings with EDS-like syndrom attributed to
a missense variant in the COL5A1 gene. (C): Underneath the unremarkable epidermis, abnormal
collagen fibers are present in the superficial and mid dermis. Collagen fibers are very short, thin, wispy,
and disorganized. Some broader, hypereosinophilic fibers are present. 200× original magnification;
bar = 50 microns. (D): In the upper dermis, horizontally aligned fibroblasts are present, indicating
reparation of previous ruptures. In between the altered collagen fibers, there are numerous extravascular
erythrocytes compatible with excessive hemorrhage. Compared to case 1 (panels A,B), large dermal
collagen clumps are not present. 400× original magnification; bar = 20 microns.
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3.2.2. Cases 2 and 3
Histological examination of the skin biopsies from these affected siblings revealed abnormal
collagen fibers characterized by a severe variability in fiber diameter ranging from thin and wispy
to normal thickness. In addition, there was a shortening of the fibers and fiber disarray. Abnormal
fibers were outlined by increased numbers of fibroblasts. Space between fibers was wider than normal,
and there was abundant hemorrhage, especially in the mid dermis. The dermis and the overlying
epidermis were of normal thickness.
3.3. Transmission Electron Microscopy
The clinical and histological features discussed above suggested that all three cases might have a
form of Ehlers–Danlos syndrome. In case 1, tissue was available for detailed ultrastructural analysis,
and transmission electron microscopy of the dermis revealed abnormal fibril architecture that was also
consistent with EDS. While in the control dermis, the collagen fibrils were highly organized and aligned
with an approximately circular cross-sectional shape of uniform diameter (Figure 7A–D), the affected dog
dermis had in addition to this normal fibril architecture a significant second heterogeneous population
of disorganized collagen fibrils with large and/or irregular cross-sectional shapes (Figure 7E–H). This
fibrillar disorganization has been widely reported in human EDS patient skin [20] and mouse models
of EDS [19] and has also been reported in dogs [11]. Unfortunately, samples were not available from
cases 2 and 3 for ultrastructural analysis of collagen fibrillar architecture.
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Figure 7. Structurally abnormal dermal collagen fibrils in Case 1. Transmission electron micrographs
from the dermis of control (A–D) and Case 1 (EDS) (E–H). Control dermis contains well-organized
collagen fibrils of uniform size and circular profile, while the EDS dermis contains two populations
of fibrils. One fibril population is similar to the control dermis, whereas the other heterogeneous
population contains large and structurally abnormal fibrils. Scale bars of 0.5 µm or 1 µm are shown.
3.4. Biochemical A alysis of Dermis
For case 1, dermal tissue was also available for biochemical analysis of the collagen composition.
Extraction with isotonic neutral pH buffer (NSS), which removes the newly synthesized collagen
species, a counted for only a small proportion of the total collagen extracted (Figur 8A, lane 1–2)
as did further extraction with Gu Cl (lanes 3–4 or acetic acid (lanes 5–6), which xtracts newly
cross-linked collagen matrix. Note that lanes 1–6 were loaded with much higher proportions of
the extrac s to achieve Coomassie-detectable bands (F gure 8A, see legend for loading details). In
all these extracts, collagen I and collagen III were the most abundant collagens with no appa ent
quantitative differenc s between EDS and control. Th pepsi extracts of the dermis (Figure 8A,
lanes 7,8) re eas d the more cross-link d collagenous matrix as evidenced by the abundance of type I
cross-li k d dimers (β-compone s) and trimers (γ-components). There was no detectable qualitative
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difference in collagen I and III ratios or collagen I cross-linking in these samples. Collagen V was
partially purified to provide additional qualitative data on the pepsin-extracted α1(V) and α2(V) chains
(Figure 8B). Both α1(V) and α2(V) chains had a normal electrophoretic migration excluding major
structural mutations affecting the α-chain size, or increased post-translational modifications, which
could indicate helix-disrupting mutations.
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Figure 8. Dermal collagen extracellular matrix composition. Samples from control dermis (C) and EDS
dermis (E) were extracted sequentially 0.15 M NaCl, 50 mM Tris-HCl buffer, pH 7.4 (neutral salt soluble,
NSS), 4 M GuHCl, 0.5 M acetic acid (AA) and digestion with pepsin (Pep) at 100 µg/mL to sequentially
extract the successively more cross-linked and thus mature collagen matrix. (A) Extracts analyzed
by SDS-polyacrylamide gel (3–8%) electrophoresis; samples unreduced. (B) Pepsin extracts where
collagen V chains were enriched by selective salt precipitation. Note that all samples were loaded to
achieve a comparable staining intensity of control and EDS sample pair in each extract and do not
reflect the relative amount of collagen between extracts. The vast majority of the collagen was found in
the pepsin extract fractions (>95%) of both the Control and EDS dermis. The migrations of collagen V
α1(V) and α2(V) and the collagen I α1(I) and α2(I) chains and cross-linked α-chain dimers (β11 and
β12) and trimers (γ112) are shown. The disulfide-bonded collagen III trimer is denoted by α1(III)3.
3.5. Genetic Analyses
3.5.1. Case 1
We sequenced the whole-genome of the affected Labrador Retriever at ~18× coverage and called
SNVs and short indels with respect to the canine reference genome (CanFam 3.1). The variants were
compared to 356 control dogs from diverse breeds. We analyzed the data under two alternative models
regarding the mode of inheritance: mon genic recessive o m nogenic dominant. For th recessiv
model, we only co sidered va iants a w ich the affected dog was homozygous for the non-reference
allele, and none of the control dogs carr ed the non-refer nce allele. Har -filtering esulted in four
privat protein-changing variants pr sent in the affected dog (Table 1). None of these variants was
located in a known candidate gene for Ehler –Danlos syndrom . When filtering for heterozygous
genotypes in th affected dog under the alternative domina t mod l, our utomated pipeline detected
31 private pro in-cha ging variants, mong them a single nucleotide deletion in the COL5A1 gene.
This vari nt, XM_022423936.1,c.3038d lG, led to a shift in the reading frame and a premature stop
codon p.(Gly1013ValfsTer260).
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Table 1. Homozygous and heterozygous private genetic variants in case 1 and case 2.
Filtering Step Number of Variants
Case 1 Case 2
homozygous variants in the whole-genome 2,791,220 2,384,739
homozygous protein-changing variants in the
whole-genome 12,121 11,065
homozygous private protein-changing variants 4 9
homozygous private protein-changing variants in
candidate genes 0 0
heterozygous variants in the whole-genome 3,080,790 4,346,318
heterozygous protein-changing variants in the
whole-genome 10,310 13,789
heterozygous private protein-changing variants 31 276
heterozygous private protein-changing variants in
candidate genes 1 1
The heterozygous genotype at this variant in case 1 was confirmed by Sanger sequencing, and the
genotypes of the parents were determined (Figure 9). In the affected dog, the ratio of wildtype:mutant
allele was ~1,1. The sire of case 1 was homozygous wildtype. In contrast, the wildtype:mutant allele
ratio was ~4,1 in DNA isolated from the blood of the affected dog’s dam, indicating that the mutation
event had occurred in the dam and that she was a gonosomal mosaic.
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Figure 9. Sanger electropherograms illustrating the c.3038delG variant in case 1 and its parents. The
sequence reads were obtained with a primer in reverse complementary orientation. While the affected
dog shows a 1,1 ratio of the two alleles indicating a heterozygous genotype, the skewed allele ratio
in the mother suggests somatic mosaicism. The mutant allele in the mother must have been present
in white blood cells and her germline. This confirms that the c.3038delG variant arose by a de novo
mutation event during the development of the mother.
3.5.2. Cases 2 and 3
We sequenced the whole-genome of case 2 at ~25× coverage. As in case 1, SNVs and short indel
variants were calle and compared to 356 ontrol dogs, nsidering both recessive and a d mi ant
mode of inherit nce. Our automated pipeline detected nine homozygous protein-changing variants in
the affected dog, but none of them in a functional candidate gene (Table 1). Hard filtering for private
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protein-changing variants present in the heterozygous state in case 2 resulted in 276 variants, including
a missense variant in the COL5A1 gene, XM_022423936.1,c.4711G>A; XP_022279644.1,p.(Gly1571Arg).
Sanger sequencing confirmed a heterozygous genotype at the variant in case 2 and the available
affected full-sibling (case 3), and the absence of the variant in 493 dogs from 66 different breeds (Table
S1). DNA from the parents was not available.
4. Discussion
The clinical presentation in all three cases was consistent with a form of EDS. The most common
form of EDS in humans, hypermobile EDS (hEDS), is an autosomal dominant condition, though the
underlying genetic mutation has not been identified. Classical EDS (cEDS) is similarly an autosomal
dominant condition, and mutations in collagen V genes (COL5A1 and COL5A2) have been reported [40].
In 2017, Malfait et al. proposed the International Classification for EDS [29]. With recent developments
in next-generation sequencing and the discovery of a number of genetic defects in collagen biosynthesis
and structure, human EDS has been reclassified into 13 subtypes based on major and minor criteria.
Diagnosis of cEDS in humans relies on fulfilling minimal criteria (Table 2) as follows: Major criterion
(1) skin hyperextensibility and atrophic scarring; plus either major criterion, (2) generalized joint
hypermobility and/or at least three minor criteria. Confirmatory molecular testing is obligatory to
reach a final diagnosis.
Table 2. Classical Ehlers–Danlos syndromes (EDS)–clinical criteria.
Major criteria 1. Skin hyperextensibility and atrophic scarring2. Generalized joint hypermobility
Minor criteria
1. Easy bruising
2. Soft, doughty skin
3. Skin fragility (or traumatic splitting)
4. Molluscoid pseudotumors
5. Subcutaneous spheroids
6. Hernia (history thereof)
7. Epicanthal folds
8. Complications of joint hypermobility (e.g., sprains,
luxation/subluxation, pain, flexible flatfoot)
9. Family history of a first-degree relative who meets clinical criteria
Adapted from Malfait et al. [29].
In case 1, the affected dog met both major criteria. One minor criterion, skin fragility, was also
noted in the case history. This animal was 9 months of age at the time of euthanasia—it is possible that
had the animal survived into adulthood more of the minor criteria would have been met. Regardless,
the diagnosis of cEDS, in this case, was confirmed by the demonstration of the 1 bp deletion mutation
introducing a premature stop codon in the COL5A1 gene.
In cases 2 and 3, the major criteria of skin hyperextensibility (case 2 and 3) and atrophic scarring
(case 2) were met; however, joint hypermobility was not evaluated. However, two minor criteria
(easy bruising and traumatic splitting of the skin) were fulfilled. The diagnosis of cEDS in case 1 was
confirmed by the demonstration of the missense mutation of the COL5A1 gene. While a missense
mutation was demonstrated in cases 2 and 3, we could not strictly confirm the diagnosis of EDS
without meeting the clinical criteria. It is worth noting that these criteria are a human EDS classification
system, and too few cases have been reported in the literature to develop such a classification system
for other species.
Some confusion has existed as to terminology as ED-like syndrome in dogs has been previously
termed cutaneous asthenia. The term cutaneous asthenia in humans is reserved for cases where
abnormalities in both collagen and elastin (cutis laxa) exist. The cutis laxa syndromes are no
longer included within the EDS classification system and have not been diagnosed in animals [18].
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Histopathology is typically pursued when heritable connective tissue disorders are suspected in
animals. Morphologic changes in the skin may be absent or subtle on light microscopy, with reported
changes typically including abnormal collagen fibers (collagen dysplasia) that are widely separated,
finer and/or paler than normal, and haphazardly arranged. An increase in dermal elastic fibers has
been described as a rare histopathologic feature of hereditary collagen dysplasia [41], but a distinction
between the various forms of hereditary connective tissue disorders cannot be made based on a
morphologic assessment of the tissue. In most cases, the ultrastructural examination is required to
confirm the collagen abnormality detected by light microscopy [41].
Histopathology of skin from the three affected dogs revealed dermal collagen dysplasia, with
collagen fibers that varied in diameter and length and were haphazardly arranged. Case 1 had
numerous, large collagen clumps throughout the dermis (Figure 6B), while this was not a prominent
feature in cases 2 and 3. Case 1 also had an increase in dermal elastic fibers, multifocally; a VVG
stain was not performed in cases 2 and 3. Cases 2 and 3 had more dermal fibroblasts and more space
between collagen fibers, but this was not a feature of case 1. The dermal thickness of case 1 could not be
compared to the control since the sections came from areas of the body with innate differences in dermal
thickness, i.e., the back and abdomen, respectively. Cases 2 and 3 had normal dermal thicknesses.
Collagen protein analysis of case 1 showed a normal collagen composition of the EDS skin
compared to the control skin, with predominantly collagen I and smaller amounts of collagen III. Both
EDS and control samples had, as expected, small amounts of collagen V, mostly in the pepsin-extracted
cross-linked collagen fraction. There was no evidence of differential solubility of any of the collagen
fractions, suggesting that the incorporation of all collagens into the dermal extracellular matrix was
not impeded by the collagen V mutation. Genetic analysis of case 1 demonstrated a heterozygous
COL5A1 p.(Gly1013ValfsTer260) mutation. Because of the introduction of a downstream premature
termination codon in the mutant allele, this would be expected to result in α1(V) mRNA instability
due to nonsense-mediated mRNA decay [42] resulting in α1(V) protein haploinsufficiency. Since α1(V)
is an essential component of all collagen V helical trimers, an overall reduction in collagen V protein
would result. A limitation of our studies is that we were unable to extract mRNA from the frozen
tissue samples available, or obtain cell lines from case 1 to directly demonstrate the nonsense-mediated
mRNA decay of the mutant COL5A1 allele. Haploinsufficiency of COL5A1 has been demonstrated
in mice and humans and since the ratio of collagen V:collagen I is important for correct collagen I
fibrillogenesis, reduced collagen V is associated with the EM findings of disorganized collagen fibrils
and the clinical phenotype of cEDS [19,21,43].
Genetic analysis of cases 2 and 3 revealed a missense variant in the COL5A1 gene, p.(Gly1571Arg).
The predicted amino acid exchange occurs in the protein helical domain, and by analogy with helix
glycine substitution mutations, in collagen I in osteogenesis imperfecta, collagen II in chondrodysplasias,
and collagen III and V in Ehlers Danlos syndrome, would be expected to disrupt collagen helix formation
and/or stability [44]. In addition, intracellular retention of this structurally abnormal collagen could
result in endoplasmic reticulum stress, which can impact cellular function. In addition, the intracellular
degradation of the mutant collagen by the cellular quality control machinery may lead to reduced
secretion of collagen V containing the mutant α1(V), also resulting in reduced extracellular collagen V
available to regulate collagen I fibrillogenesis. Furthermore, any secretion of the mutant collagen V
may interfere with collagen interactions in the extracellular matrix [44]. Unfortunately, neither dermal
tissues nor cells were available from these dogs to directly explore these pathological mechanisms.
Interestingly, in case 1, the variant was passed on from a clinically non-affected mosaic parent to
the offspring. It is, however, unknown whether the mother was clinically completely normal or showed
subtle signs of Ehlers–Danlos syndrome. The genetic analysis of case 1 and its parents confirmed the
suspected de novo mutation event. Given that only one protein-changing de novo mutation event per
generation is expected on average, this further strongly supports the causality of the variant for the
EDS phenotype. We speculated that a similar independent de novo mutation event had happened in
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one of the parents of cases 2 and 3. Unfortunately, no DNA samples from their parents were available,
and we could not verify this assumption.
Our results were also consistent with recent findings in a cat that was also affected by
Ehlers–Danlos syndrome due to a de novo mutation in the COL5A1 gene [45]. A recent paper
demonstrated an 8-week-old Doberman Pinscher puppy with EDS to carry a rare, homozygous C-to-T
transition at position 2408978 on chromosome 11. This transition is predicted to alter the ADAMTS2
transcript (ADAMTS2,c.769C>T) and represents a nonsense variant (p.Arg257Ter) [46]. Whole-genome
sequencing of another mixed-breed dog with EDS revealed two missense variants in the TNXB gene,
encoding the extracellular matrix protein tenascin XB as potential candidate causative variants for
EDS [47]. To the authors’ knowledge, no previous studies have shown genetic variants in the COL5A1
gene in the dog.
These studies show that whole-genome sequencing as part of a “precision medicine” approach
can be a valuable tool to obtain a precise definition of the molecular lesion in domestic animal patients
suspected to suffer from inherited disease.
5. Conclusions
To the best of our knowledge, we provided the first report of genetic variants in the COL5A1
gene that are associated with the clinical presentation of EDS in dogs. Molecular screening using
whole-genome or whole-exome sequencing or the targeted resequencing of a gene panel that includes
the known EDS candidate genes from other species is a viable tool in the diagnosis of EDS in dogs. As
in humans, any molecular techniques should always be combined with the established clinical criteria
to confirm a diagnosis of EDS.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/10/731/s1.
Table S1. COL5A1,c.4711G>A genotypes of 493 dogs from 66 different dog breeds.
Author Contributions: All authors have read and approved the manuscript, A.B. performed the genetic
analysis and contributed to writing, J.F.B. was involved in biochemical analysis of tissue samples, study design,
and contributed to writing the manuscript, S.R.L. was involved in biochemical analysis of tissue samples and
contributed to writing the manuscript, E.H. conducted the transmission electron microscopy, S.G.M.K. was involved
in interpretation of histology for case 1 and contributed to writing, M.Y. was involved in case management, tissue
collection, and clinical images, A.R. identified the cases from Morocco and was involved in clinical management
and sample acquisition, V.J. performed the bioinformatics processing of the whole-genome sequence data and
handled sequence data deposition to the ENA, M.W. performed the histopathological analyses on the cases
from Morocco and contributed to writing the manuscript, T.L. supervised the genetic analysis and contributed
to manuscript writing, F.L.B. was involved in clinical case management, sample collection, and was a major
contributor in writing manuscript.
Funding: This study was funded in part by a grant of the Swiss National Science Foundation (CRSII3_160738) for
genomic analysis and interpretation of data and by funding to the Murdoch Children’s Research Institute
from the Victorian Government’s Operational Infrastructure Support Program for sample collection and
biochemical analysis.
Acknowledgments: The Next-Generation Sequencing Platform of the University of Bern is acknowledged for
performing the whole-genome re-sequencing experiment and the Interfaculty Bioinformatics Unit of the University
of Bern for providing computational infrastructure. We acknowledge the Dog Biomedical Variant Database
Consortium (Gus Aguirre, Catherine André, Danika Bannasch, Doreen Becker, Brian Davis, Cord Dröegemüller,
Kari Ekenstedt, Kiterie Faller, Oliver Forman, Steve Friedenberg, Eva Furrow, Urs Giger, Christophe Hitte, Marjo
Hytönen, Vidhya Jagannathan, Tosso Leeb, Hannes Lohi, Cathryn Mellersh, Jim Mickelson, Anita Oberbauer,
Jeffrey Schoenebeck, Kim Summers, Frank van Steenbeck, Claire Wade) for sharing whole-genome sequencing
data from control dogs and wolves. We thank all owners for donating samples and additional data of their animals.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Solomons, B. Equine cutis hyperelastica. Equine Vet. J. 1984, 16, 541–542. [CrossRef] [PubMed]
2. Hegreberg, G.A. Animal model: Ehlers-Danlos syndrome in dogs and mink, canine cutaneous asthenia.
Am. J. Pathol. 1975, 79, 383–386. [PubMed]
Genes 2019, 10, 731 14 of 16
3. Harvey, R.G.; Brown, P.J.; Young, R.D.; Whitbread, T.J. A connective tissue defect in two rabbits similar to the
Ehlers-Danlos syndrome. Vet. Rec. 1990, 126, 130–132. [PubMed]
4. Minor, R.R.; Lein, D.H.; Patterson, D.F.; Krook, L.; Porter, T.G.; Kane, A.C. Defects in collagen fibrillogenesis
casuing hyperextensible, fragile skin in dogs. J. Am. Vet. Med. Assoc. 1983, 182, 142–148. [PubMed]
5. Persechino, A.G.; Roperto, F.; de Capraris, D.; Troncone, A. Rilievi clinici ed istopatologici in una
collagenopatia del cane riportabile alla sindrome di Ehlers-Danlos dell’uomo [Collagenopathy in a dog
resembling Ehlers-Danlos syndrome of man. Clinical and histopathological features]. Acta Med. Vet. 1983,
29, 67–79.
6. Papparella, S.R.; Troncone, A. Sindrome di Elhers-Dan-los nel cane. Rilievi ultrastrutturali della cute
[Elhers-Danlos syndrome in a dog. Ultrastructural findings of the skin]. Acta Med. Vet. 1988, 34, 207–213.
7. Rodriguez, F.; Herráez, P.; Monteros, A.E.D.L.; Calabuig, P.; Rodríguez, J.L. Collagen dysplasia in a litter of
Garafiano shepherd dogs. Zent. Fur Vet. Reihe A 1996, 43, 509–512.
8. Barnett, K.C.; Cottrell, B.D. Ehlers-Danlos syndrome in a dog: Ocular, cutaneous and articular abnormalities.
J. Small Anim. Pract. 1987, 28, 941–946. [CrossRef]
9. Paciello, O.; Lamagna, F.; Lamagna, B.; Papparella, S. Ehlers-Danlos-like syndrome in 2 dogs: Clinical,
histologic, and ultrastructural findings. Vet. Clin. Pathol. 2003, 32, 13–18. [CrossRef]
10. Barrera, R.; Mane, C.; Duran, E.; Vives, M.A.; Zaragoza, C. Ehlers-Danlos syndrome in a dog. Can. Vet. J.
2004, 45, 355–356.
11. Bellini, M.H.; Caldini, E.T.E.G.; Scapinelli, M.P.; Simões, M.J.; Machado, D.B.; Nürmberg, R.; Simões, M.
Increased elastic microfibrils and thickening of fibroblastic nuclear lamina in canine cutaneous asthenia.
Vet. Dermatol. 2009, 20, 139–143. [CrossRef]
12. Rasch, S.N. Surgical and medical treatment of ocular disease in a dog with Ehlers–Danlos syndrome. Clin.
Case Rep. 2017, 5, 880–886. [CrossRef]
13. Uri, M.; Verin, R.; Ressel, L.; Buckley, L.; McEwan, N. Ehlers–Danlos Syndrome Associated with Fatal
Spontaneous Vascular Rupture in a Dog. J. Comp. Pathol. 2015, 152, 211–216. [CrossRef]
14. Ueda, K.; Kawai, T.; Senoo, H.; Shimizu, A.; Ishiko, A.; Nagata, M. Histopathological and electron microscopic
study in dogs with patellar luxation and skin hyperextensibility. J. Vet. Med. Sci. 2018, 80, 1309–1316.
[CrossRef] [PubMed]
15. Counts, D.F.; Byers Holbrook, K.A.; Hegreberg, G.A. Dermatosparaxis in a Himalyan cat. J. Investig. Dermatol.
1980, 74, 96–99. [CrossRef]
16. Sequeira, J.L.; Bandarra, E.P.; Figueiredo, L.M.A.; Eugenio, F.R.; Rocha, N.S. Collagen Dysplasia (Cutaneous
Asthenia) in a Cat. Vet. Pathol. 1999, 36, 603–606. [CrossRef] [PubMed]
17. Holbrook, K.A.; Byers, P.H.; Counts, D.F.; Hegreberg, G.A. Dermatosparaxis in a Himalayan cat. II.
Ultrastructural studies of dermal collagen. J. Investig. Dermatol. 1980, 74, 100–104. [CrossRef] [PubMed]
18. Scott, D.W.; Miller, W.H.; Griffin, C.E. Congenital and Hereditary Diseases. In Muller and Kirk’s Small Animal
Dermatology, 6th ed.; Scott, D.W., Miller, W.H., Griffin, C.E., Eds.; WB Saunders: Philadelphia, PA, USA, 2001;
pp. 913–1003.
19. Wenstrup, R.J.; Florer, J.B.; Davidson, J.M.; Phillips, C.L.; Pfeiffer, B.J.; Menezes, D.W.; Chervoneva, I.;
Birk, D.E. Murine Model of the Ehlers-Danlos Syndrome COL5A1 haploinsufficiency disrupts collagen fibril
assembly at multiple stages. J. Biol. Chem. 2006, 281, 12888–12895. [CrossRef]
20. Bouma, P. COL5A1 Exon 14 Splice Acceptor Mutation Causes a Functional Null Allele, Haploinsufficiency of
alpha 1(V) and Abnormal Heterotypic Interstitial Fibrils in Ehlers-Danlos Syndrome II. J. Biol. Chem. 2001,
276, 13356–13364. [CrossRef]
21. Symoens, S.; Syx, D.; Malfait, F.; Callewaert, B.; De Backer, J.; Vanakker, O.; Coucke, P.; De Paepe, A.
Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with
classic EDS and allows to refine diagnostic criteria. Hum. Mutat. 2012, 33, 1485–1493. [CrossRef]
22. Wenstrup, R.J.; Langland, G.T.; Willing, M.C.; D’Souza, V.N.; Cole, W.G. A splice-junction mutation in the
region of COL5A1 that codes for the carboxyl propeptide of pro alpha 1(V) chains results in the gravis form
of the Ehlers-Danlos syndrome (type I). Hum. Mol. Genet. 1996, 5, 1733–1736. [CrossRef] [PubMed]
23. De Paepe, A.; Nuytinck, L.; Hausser, I.; Anton-Lamprecht, I.; Naeyaert, J.M. Mutations in the COL5A1 gene
are causal in the Ehlers-Danlos syndromes I and II. Am. J. Hum. Genet. 1997, 60, 547–554. [PubMed]
Genes 2019, 10, 731 15 of 16
24. Nicholls, A.C.; E Oliver, J.; McCarron, S.; Harrison, J.B.; Greenspan, D.S.; Pope, F.M. An exon skipping
mutation of a type V collagen gene (COL5A1) in Ehlers-Danlos syndrome. J. Med. Genet. 1996, 33, 940–946.
[CrossRef] [PubMed]
25. Richards, A.J.; Martin, S.; Nicholls, A.C.; Harrison, J.B.; Pope, F.M.; Burrows, N.P. A single base mutation in
COL5A2 causes Ehlers-Danlos syndrome type II. J. Med. Genet. 1998, 35, 846–848. [CrossRef] [PubMed]
26. Toriello, H.V.; Glover, T.W.; Takahara, K.; Byers, P.H.; Miller, D.E.; Higgins, J.V.; Greenspan, D.S. A
translocation interrupts the COL5A1 gene in a patient with Ehlers–Danlos syndrome and hypomelanosis of
Ito. Nat. Genet. 1996, 13, 361–365. [CrossRef]
27. Birk, D.E. Type V collagen: Heterotypic type I/V collagen interactions in the regulation of fibril assembly.
Micron (Oxf. Engl. 1993) 2001, 32, 223–237. [CrossRef]
28. Hausser, I.; Anton-Lamprecht, I. Differential ultrastructural aberrations of collagen fibrils in Ehlers-Danlos
syndrome types I–IV as a means of diagnostics and classification. Qual. Life Res. 1994, 93, 394–407. [CrossRef]
29. Malfait, F.; Francomano, C.; Byers, P.; Belmont, J.; Berglund, B.; Black, J.; Bloom, L.; Bowen, J.M.; Brady, A.F.;
Burrows, N.P.; et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am. J. Med. Genet.
C Semin. Med. Genet. 2017, 175, 8–26. [CrossRef]
30. Bateman, J.F.; Golub, S.B. Deposition and selective degradation of structurally-abnormal type I collagen in
a collagen matrix produced by osteogenesis imperfecta fibroblasts in vitro. Matrix Biol. 1994, 14, 251–262.
[CrossRef]
31. Niyibizi, C.; Fietzek, P.P.; van der Rest, M. Human placenta type V collagens. Evidence for the existence of
an alpha 1(V) alpha 2(V) alpha 3(V) collagen molecule. J. Biol. Chem. 1984, 259, 14170–14174.
32. Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics
2009, 25, 1754–1760. [CrossRef] [PubMed]
33. Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and population
genetical parameter estimation from sequencing data. Bioinformatics 2011, 27, 2987–2993. [CrossRef]
[PubMed]
34. McKenna, A.; Hanna, M.; Banks, E.; Sivachenko, A.; Cibulskis, K.; Kernytsky, A.; Garimella, K.; Altshuler, D.;
Gabriel, S.; Daly, M.; et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing
next-generation DNA sequencing data. Genome Res. 2010, 20, 1297–1303. [CrossRef] [PubMed]
35. Bai, B.; Zhao, W.M.; Tang, B.X.; Wang, Y.Q.; Wang, L.; Zhang, Z.; Yang, H.C.; Liu, Y.H.; Zhu, J.W.; Irwin, D.M.;
et al. DoGSD: The dog and wolf genome SNP database. Nucleic Acids Res. 2015, 43, D777–D783. [CrossRef]
[PubMed]
36. Van der Auwera, G.A.; Carneiro, M.O.; Hartl, C.; Poplin, R.; Del Angel, G.; Levy-Moonshine, A.; Jordan, T.;
Shakir, K.; Roazen, D.; Thibault, J.; et al. From FastQ data to high confidence variant calls: The Genome
Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinform. 2013, 43, 11.10.1–11.10.33.
37. Cingolani, P.; Platts, A.; Wang, L.L.; Coon, M.; Nguyen, T.; Wang, L.; Land, S.J.; Lu, X.; Ruden, D.M. A
program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the
genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 2012, 6, 80–92. [CrossRef]
38. Patterson, D.F.; Minor, R.R. Hereditary fragility and hyper-extensibility of the skin of cats. Lab. Investig. 1977,
37, 170. [PubMed]
39. Freeman, L.J.; Hegreberg, G.A.; Robinette, J.D. Ehlers-Danlos syndrome in dogs and cats. Semin. Vet. Med.
Surg. Small Anim. 1987, 2, 221–227. [PubMed]
40. Joseph, A.W.; Joseph, S.S.; Francomano, C.A.; Kontis, T.C. Characteristics, Diagnosis, and Management of
Ehlers-Danlos Syndromes: A Review. JAMA Facial Plast. Surg. 2018, 20, 70–75. [CrossRef]
41. Mauldin, E.; Peters-Kennedy, J. Integumentary System. In Jubb, Kennedy, and Palmer’s Pathology of Domestic
Animals, 6th ed.; Grant Maxie, M., St Louis, M.O., Eds.; Elsevier Inc.: Amsterdam, The Netherlands, 2016;
pp. 542–546.
42. Fang, Y.; Bateman, J.F.; Mercer, J.F.; Lamande, S.R. Nonsense-mediated mRNA decay of collagen-emerging
complexity in RNA surveillance mechanisms. J. Cell Sci. 2013, 126, 2551–2560. [CrossRef]
43. DeNigris, J.; Yao, Q.; Birk, E.K.; Birk, D.E. Altered dermal fibroblast behavior in a collagen V haploinsufficient
murine model of classic Ehlers-Danlos syndrome. Connect Tissue Res. 2016, 57, 1–9. [CrossRef] [PubMed]
44. Bateman, J.F.; Boot-Handford, R.P.; Lamandé, S.R. Genetic diseases of connective tissues: Cellular and
extracellular effects of ECM mutations. Nat. Rev. Genet. 2009, 10, 173–183. [CrossRef] [PubMed]
Genes 2019, 10, 731 16 of 16
45. Spycher, M.; Bauer, A.; Jagannatha, V.; Frizzi, M.; De Lucia, M.; Leeb, T. A frameshift variant in the COL5A1
gene in a cat with Ehlers-Danlos syndrome. Anim. Genet. 2018, 49, 641–644. [CrossRef] [PubMed]
46. Jaffey, J.A.; Bullock, G.; Teplin, E.; Guo, J.; Villani, N.A.; Mhlanga-Mutangadura, T.; Schnabel, R.D.; Cohn, L.A.;
Johnson, G.S. A homozygous ADAMTS2 nonsense mutation in a Doberman Pinscher dog with Ehlers Danlos
syndrome and extreme skin fragility. Anim. Genet. 2019, 50, 543–545. [CrossRef] [PubMed]
47. Bauer, A.; de Lucia, M.; Leuthard, F.; Jagannathan, V.; Leeb, T. Compound heterozygosity for TNXB genetic
variants in a mixed-breed dog with Ehlers-Danlos syndrome. Anim. Genet. 2019, 50, 546–549. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
